Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$220.05 +1.8%	$201.39	$163.81 ▼ $221.76	$388.92B	0.53	6.44 million shs	3.26 million shs
ABT Abbott Laboratories	$133.51 +0.6%	$130.35	$110.86 ▼ $141.23	$232.61B	0.69	6.63 million shs	2.91 million shs
AZN AstraZeneca	$77.65 +0.1%	$76.27	$61.24 ▼ $82.41	$240.63B	0.37	5.08 million shs	3.49 million shs
MRK Merck & Co., Inc.	$81.01 -0.1%	$82.93	$73.31 ▼ $119.38	$202.38B	0.37	15.00 million shs	6.52 million shs
NVS Novartis	$122.60 -0.2%	$121.76	$96.06 ▼ $130.46	$259.01B	0.63	1.88 million shs	952,969 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.76%	+2.76%	+4.66%	+16.74%	+10.47%
ABT Abbott Laboratories	+1.04%	+0.55%	+0.84%	+0.31%	+12.86%
AZN AstraZeneca	-0.63%	-4.51%	-2.03%	+9.61%	-1.87%
MRK Merck & Co., Inc.	0.00%	-4.30%	-3.89%	+2.28%	-31.27%
NVS Novartis	-0.31%	-4.10%	-1.05%	+5.97%	+5.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$220.05 +1.8%	$201.39	$163.81 ▼ $221.76	$388.92B	0.53	6.44 million shs	3.26 million shs
ABT Abbott Laboratories	$133.51 +0.6%	$130.35	$110.86 ▼ $141.23	$232.61B	0.69	6.63 million shs	2.91 million shs
AZN AstraZeneca	$77.65 +0.1%	$76.27	$61.24 ▼ $82.41	$240.63B	0.37	5.08 million shs	3.49 million shs
MRK Merck & Co., Inc.	$81.01 -0.1%	$82.93	$73.31 ▼ $119.38	$202.38B	0.37	15.00 million shs	6.52 million shs
NVS Novartis	$122.60 -0.2%	$121.76	$96.06 ▼ $130.46	$259.01B	0.63	1.88 million shs	952,969 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.76%	+2.76%	+4.66%	+16.74%	+10.47%
ABT Abbott Laboratories	+1.04%	+0.55%	+0.84%	+0.31%	+12.86%
AZN AstraZeneca	-0.63%	-4.51%	-2.03%	+9.61%	-1.87%
MRK Merck & Co., Inc.	0.00%	-4.30%	-3.89%	+2.28%	-31.27%
NVS Novartis	-0.31%	-4.10%	-1.05%	+5.97%	+5.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.93	Moderate Buy	$222.68	0.99% Upside
ABT Abbott Laboratories	2.91	Moderate Buy	$144.47	8.41% Upside
AZN AstraZeneca	2.75	Moderate Buy	$86.00	10.58% Upside
MRK Merck & Co., Inc.	2.33	Hold	$106.41	30.29% Upside
NVS Novartis	2.00	Hold	$120.33	-1.88% Downside

Current Analyst Ratings Breakdown

Latest NVS, MRK, AZN, ABBV, and ABT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2025	ABBV AbbVie	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$170.00 ➝ $270.00
9/17/2025	MRK Merck & Co., Inc.	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$100.00 ➝ $90.00
9/16/2025	ABBV AbbVie	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$200.00 ➝ $235.00
9/15/2025	ABBV AbbVie	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$215.00 ➝ $245.00
9/12/2025	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$240.00 ➝ $260.00
9/12/2025	ABBV AbbVie	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$215.00 ➝ $240.00
9/12/2025	NVS Novartis	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell	$119.00 ➝ $118.00
8/25/2025	ABBV AbbVie	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/21/2025	NVS Novartis	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$231.00
8/11/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.91	$15.13 per share	14.57	$1.90 per share	116.05
ABT Abbott Laboratories	$41.95B	5.53	$6.68 per share	19.95	$27.62 per share	4.83
AZN AstraZeneca	$54.07B	4.46	$6.27 per share	12.40	$13.18 per share	5.90
MRK Merck & Co., Inc.	$64.17B	3.18	$9.54 per share	8.56	$18.33 per share	4.46
NVS Novartis	$50.32B	5.15	$10.65 per share	11.52	$21.59 per share	5.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	104.83	15.77	1.40	6.45%	699.66%	13.64%	10/29/2025 (Estimated)
ABT Abbott Laboratories	$13.40B	$7.98	16.70	23.26	2.49	32.43%	18.32%	10.71%	10/15/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.66	29.21	15.56	1.43	14.68%	32.84%	12.87%	11/11/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.49	12.57	8.25	0.83	25.79%	41.05%	16.55%	10/30/2025 (Estimated)
NVS Novartis	$11.94B	$6.87	17.84	13.92	1.72	25.64%	41.08%	16.83%	11/4/2025 (Estimated)

Latest NVS, MRK, AZN, ABBV, and ABT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/15/2025	Q3 2025	ABT Abbott Laboratories	$1.30	N/A	N/A	N/A	$11.40 billion	N/A
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion
7/29/2025	Q2 2025	AZN AstraZeneca	$1.09	$1.09	N/A	$0.79	$14.08 billion	$14.46 billion
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	$2.13	+$0.10	$1.76	$15.92 billion	$15.81 billion
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.26	$1.26	N/A	$1.01	$11.01 billion	$11.14 billion
7/17/2025	Q2 2025	NVS Novartis	$2.38	$2.42	+$0.04	$2.06	$13.94 billion	$14.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	2.98%	N/A	312.38%	53 Years
ABT Abbott Laboratories	$2.36	1.77%	N/A	29.57%	54 Years
AZN AstraZeneca	$1.01	1.30%	N/A	37.97%	N/A
MRK Merck & Co., Inc.	$3.24	3.97%	N/A	49.92%	14 Years
NVS Novartis	$2.60	2.12%	N/A	37.85%	N/A

Latest NVS, MRK, AZN, ABBV, and ABT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/5/2025	ABBV AbbVie	quarterly	$1.64	3.08%	10/15/2025	10/15/2025	11/14/2025
7/22/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4%	9/15/2025	9/15/2025	10/7/2025
7/29/2025	AZN AstraZeneca	semi-annual	$0.5050	2%	8/8/2025	8/8/2025	9/8/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
ABT Abbott Laboratories	0.25	1.82	1.30
AZN AstraZeneca	0.55	0.86	0.67
MRK Merck & Co., Inc.	0.69	1.42	1.17
NVS Novartis	0.53	0.82	0.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ABT Abbott Laboratories	75.18%
AZN AstraZeneca	20.35%
MRK Merck & Co., Inc.	76.07%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
ABT Abbott Laboratories	0.46%
AZN AstraZeneca	N/A
MRK Merck & Co., Inc.	0.09%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.77 billion	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
MRK Merck & Co., Inc.	75,000	2.50 billion	2.50 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable

NVS, MRK, AZN, ABBV, and ABT Headlines

Recent News About These Companies

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

5 hours ago | zacks.com

Novartis AG $NVS Shares Sold by Acadian Asset Management LLC

September 17 at 3:19 AM | marketbeat.com

Novartis AG $NVS Shares Bought by Baker Ellis Asset Management LLC

September 16 at 6:46 AM | marketbeat.com

Douglas Lane & Associates LLC Cuts Stake in Novartis AG $NVS

September 16 at 5:01 AM | marketbeat.com

Novartis AG $NVS Shares Sold by Arvest Investments Inc.

September 16 at 4:29 AM | marketbeat.com

Rhumbline Advisers Raises Stock Position in Novartis AG $NVS

September 16 at 3:49 AM | marketbeat.com

Focus Partners Wealth Buys 6,849 Shares of Novartis AG $NVS

September 16 at 3:07 AM | marketbeat.com

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments

September 15 at 11:29 AM | benzinga.com

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition

September 15 at 9:59 AM | msn.com

Novartis, Monte Rosa strike $5.7 billion drug development deal

September 15 at 7:15 AM | reuters.com

3,124 Shares in Novartis AG $NVS Acquired by Integrity Alliance LLC.

September 15 at 4:20 AM | marketbeat.com

Novartis AG $NVS Stock Holdings Lowered by Bayforest Capital Ltd

September 15 at 4:08 AM | marketbeat.com

Modern Wealth Management LLC Purchases New Position in Novartis AG $NVS

September 15 at 3:52 AM | marketbeat.com

Novartis (NYSE:NVS) Shares Gap Down - Here's What Happened

September 14 at 11:27 AM | marketbeat.com

Novartis (NYSE:NVS) Earns Sell Rating from The Goldman Sachs Group

September 14 at 8:14 AM | marketbeat.com

Osterweis Capital Management Inc. Raises Position in Novartis AG $NVS

September 14 at 5:57 AM | marketbeat.com

Novartis AG $NVS Holdings Raised by Advisors Capital Management LLC

September 14 at 5:07 AM | marketbeat.com

Novartis (NYSE:NVS) Given "Sell" Rating at The Goldman Sachs Group

September 14 at 2:53 AM | americanbankingnews.com

Geneos Wealth Management Inc. Acquires 3,126 Shares of Novartis AG $NVS

September 13, 2025 | marketbeat.com

SCS Capital Management LLC Invests $586,000 in Novartis AG $NVS

September 13, 2025 | marketbeat.com

Novartis AG $NVS Shares Purchased by Great Lakes Advisors LLC

September 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVS, MRK, AZN, ABBV, and ABT Company Descriptions

AbbVie NYSE:ABBV

$220.05 +3.79 (+1.75%)

As of 03:27 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories NYSE:ABT

$133.51 +0.75 (+0.57%)

As of 03:27 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

AstraZeneca NASDAQ:AZN

$77.64 +0.09 (+0.11%)

As of 03:27 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Merck & Co., Inc. NYSE:MRK

$81.01 -0.08 (-0.10%)

As of 03:27 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis NYSE:NVS

$122.60 -0.19 (-0.15%)

As of 03:26 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVS, MRK, AZN, ABBV, and ABT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVS, MRK, AZN, ABBV, and ABT Earnings

Compare Dividends

Latest NVS, MRK, AZN, ABBV, and ABT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVS, MRK, AZN, ABBV, and ABT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVS, MRK, AZN, ABBV, and ABT Company Descriptions

AbbVie NYSE:ABBV

Abbott Laboratories NYSE:ABT

AstraZeneca NASDAQ:AZN

Merck & Co., Inc. NYSE:MRK

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools